RecruitingRecruiting
Phase 1 Trial to Study JANX013 and JANX007 Combination in mCRPC
NCT07813637 · Janux Therapeutics
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
A Phase 1 Open-Label, Multicenter Study of JANX013 Combined With JANX007 in Participants With Metastatic Castration Resistant Prostate Cancer
About this study
This study is a first-in human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX013 in combination with JANX007 in adults with metastatic castration-resistant prostate cancer (mCRPC).
Eligibility criteria
Key Inclusion Criteria:
* Male participants ≥ 18 years of age at the time of signing informed consent
* Histologically or cytologically confirmed adenocarcinoma of the prostate
For Dose Escalation:
\- Have received at least 1 novel ARPI (e.g., abiraterone acetate, enzalutamide, apalutamide, or darolutamide) in any setting and have received at least 1 taxane regimen (in any setting), or who are medically unsuitable or have actively refused treatment with a taxane regimen.
For Dose Expansion:
* Must be in the first-line or second-line setting for mCRPC or metastatic androgen pathway modulation resistant disease and must have received 1 novel ARPI in any setting.
* Adequate organ function
Key Exclusion Criteria:
* Prior treatment with any chimeric antigen receptor (CAR) T-cell therapy, any approved or investigational TCE, or any T-cell costimulatory agent
* Clinically significant cardiovascular disease
* Prior solid organ transplant
Study design
Enrollment target: 110 participants
Allocation: non_randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2026-09-10
Estimated completion: 2030-07
Last updated: 2026-09-17
Interventions
Drug: JANX013Drug: JANX007Drug: JANX013Drug: JANX007
Primary outcomes
- • Incidence of adverse events (AEs), serious adverse events (SAEs), and dose-limiting toxicities (DLTs) (2 years)
- • Incidence of cytokine release syndrome (CRS) (2 years)
Sponsor
Janux Therapeutics · industry
Contacts & investigators
ContactJanux Therapeutics, MD · contact · PSMA-013-001_ct.gov@januxrx.com · 1-858-206-8471
All locations (1)
Sarah Cannon Research InstituteRecruiting
Nashville, Tennessee, United States